Atherogenic Index and High-Density Lipoprotein Cholesterol as Cardiovascular Risk Determinants in Rheumatoid Arthritis: The Impact of Therapy with Biologicals

Table 1

Short-term effects of anti-TNF drugs on atherogenic index and other ratios.

Study	Drug	Number of patients	Duration	Effect
				AI	Other ratios
Popa et al. [24]	ADA	33	2 wk	L	LDL : HDL
Wijbrandts et al. [32]	ADA	50	16 wk	L	apoB : apoA-1
Gonzalez-Juanatey et al. [45]	ADA	8	12 wk	L	—
Kume et al. [21]	ADA/ETN	42	24 wk	n	—
Seriolo et al. [26]	ADA/ETN/IFX	34	24 wk	n	—
Soubrier et al. [28]	ADA/ETN/IFX	29	14 wk	n	apoB : apoA-1
Jamnitski et al. [19]	ETN	292	16 wk	L	apoB : apoA-1
Allanore et al. [15]	IFX	56	30 wk	n	LDL : HDL
Popa et al. [11]	IFX	45	24 wk	H	—
Dahlqvist et al. [17]	IFX	52	24 wk	H	—
Popa et al. [25]	IFX	55	24 wk	H	—
Tam et al. [30]	IFX	19	14 wk	n	LDL : HDL
Vis et al. [31]	IFX	69	6 wk	n	—
Engvall et al. [18]	IFX	40	14 wk	—	apoB : apoA-1
Ajeganova et al. [14]	ADA/ETN/IFX	162	24 wk	—	apoB : apoA-1
Curtis et al. [16]	not specified	289	8 wk	L	—

ETN: etanercept, ADA: adalimumab, IFX: infliximab, AI: atherogenic index, wk: weeks, L: lower, n: neutral, H: higher.